Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity and Treatment Regimens of VTP-300 Combined With Low-dose Nivolumab in Chronic Hepatitis B Infection

Next Previous
Search
Trial Profile

A Phase 2b, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity and Treatment Regimens of VTP-300 Combined With Low-dose Nivolumab in Chronic Hepatitis B Infection

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; VTP 300 (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Barinthus Biotherapeutics

    • Most Recent Events

    • 10 Jan 2025 According to Barinthus Biotherapeutics media release, results from this study are expected in the second quarter of 2025.
    • 10 Jan 2025 According to Barinthus Biotherapeutics media release, the Company will not invest in VTP-300 in chronic hepatitis B beyond the completion of this study, and will further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identified, who are able to take advantage of this therapy to achieve sustained HBsAg loss and functional cure in patients with low levels of HBsAg.
    • 31 Oct 2024 According to Barinthus Biotherapeutics media release, updated clinical data from this trial will be highlighted as a late breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting 2024 being held November 15-19, 2024 in San Diego, California.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top